Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Galena Biopharma Inc    GALE   US3632561086

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
1.47(c) 1.475(c) 1.41(c) 1.38(c) 1.35(c) Last
3 900 426 2 678 690 3 175 616 2 881 333 3 762 605 Volume
+0.68% +0.34% -4.41% -2.13% -2.17% Change
More quotes
Financials ($)
Sales 2015 16,4 M
EBIT 2015 -45,7 M
Net income 2015 -42,5 M
Debt 2015 -
Yield 2015 -
Sales 2016 26,2 M
EBIT 2016 -39,4 M
Net income 2016 -38,2 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 12,6x
Capi. / Sales 2016 7,92x
Capitalization 208 M
More Financials
Company
Galena Biopharma, Inc. is a biotechnology company focused on discovering, developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.It currently develops peptide antigenbased off the shelf cancer immunotherapies for... 
Sector
Pharmaceuticals
Calendar
05/18Earnings Release
More about the company
Surperformance© ratings of Galena Biopharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on GALENA BIOPHARMA INC
03/26 GALENA BIOPHARMA : Expands Patient Population in NeuVax(TM) (nelipepimut-S) and ..
03/18 Galena Biopharma Announces Closing of Public Offering of Common Stock and War..
03/16 GALENA BIOPHARMA : Entry into a Material Definitive Agreement, Other Events, Fin..
03/13 Galena Biopharma Announces Pricing of Public Offering of Common Stock and War..
03/12 GALENA BIOPHARMA : Announces Proposed Public Offering of Common Stock and Warran..
03/12 Galena Biopharma Announces Proposed Public Offering of Common Stock and Warra..
03/07 GALENA BIOPHARMA : Reports Fourth Quarter and Year End 2014 Financial Results
03/05 GALENA BIOPHARMA : reports 4Q loss
More news
Sector news : Pharmaceuticals - NEC
03/28 GLAXOSMITHKLINE : GSK statement on meningitis vaccination in the UK
03/27 HOSPIRA : first biosimilar could be its first to gain FDA approval
03/27 VALEANT PHARMACEUTICALS INTL : S&P Dow Jones Indices Announces Changes to the S&..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/27 Five Lessons From Ohr Pharma
03/26 Galena expands patient population in NeuVax breast cancer trial
03/13 Midday Gainers / Losers
03/13 Galena prices equity offering
03/13 Premarket Gainers / Losers


Comments 
Advertisement
Chart GALENA BIOPHARMA INC
Duration : Period :
Galena Biopharma Inc Technical Analysis Chart | GALE | US3632561086 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF